A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
A phase 2 trial of Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab emtansine and Atezolizumab in advanced solid tumours, run by Genentech, Inc., active and no longer recruiting.
Overview
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies is a phase 2 interventional study registered as NCT00781612 by Genentech, Inc., with 378 participants enrolled, started 2008-10-16 and due to reach its primary completion in 2027-06-30. Interventions recorded: Docetaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine and Atezolizumab.
Similar pages
not linked directly; found by shared links- TrialA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Shares Pertuzumab, Flatiron Health (Roche), Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Shares Trastuzumab emtansine, Flatiron Health (Roche), Atezolizumab, Trastuzumab and the tag pipeline.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Shares Flatiron Health (Roche), Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Pertuzumab, Docetaxel, Trastuzumab and the tag pipeline.
- TrialAn Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Shares Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Shares Pertuzumab, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTreatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Shares Pertuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.